Moon J. Noh, Ph.D.
Chief Executive Officer
Dr. Moon J. Noh has been with Kolon TissueGene for over 16 years. Prior to his role here, Dr. Noh was the Director of the Biotechnology Lab at Kolon Central Research Park. Dr. Noh holds a Ph.D. and M.S. from the Korea Advanced Institute of Science and Technology in Molecular Biology.
Chief Financial Officer
Soon-Wook Kweon joined Kolon TissueGene, Inc. in May, 2017 as the Chief Financial Officer. Before he joined Kolon TissueGene, he served as the Vice President of the Management & Finance Division in Kolon Corporation. He received his Bachelor of Arts in Economics at Korea University in Korea.
Benjamin P. Lewis, Pharm.D., Ph.D.
Vice President, Regulatory Affairs
Dr. Lewis joined Kolon TissueGene (KTG) in July 2018. Prior to joining KTG he served as Head of regulatory affairs North America, Mitsubishi Tanabe Pharma America; Vice President, regulatory affairs, Prestwick Pharmaceuticals (provided the regulatory leadership for the development of the first drug for Huntington's disease); Head of regulatory affairs, Brand Institute (gained FDA approval for thirteen prominent brand names for major pharma firms); and FDA (director, regulatory operations, CBER; pharmacist director, office of center director, CBER; and scientific reviewer in CDER and Orphan Products).
His extensive FDA experience provides him with firsthand knowledge of FDA regulations, guidances, and procedures as well as management, clinical review, and regulatory submission experience in a broad range of therapeutic areas. Dr. Lewis received his pharmacy degree from Auburn University; he has a MS in pharmaceutical sciences, and PhD in health services administration. He did post-graduate studies at Johns Hopkins University. Dr. Lewis is regulatory affairs certified and is the author/editor of four books.